A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Trial ID # NCT04739800; NRG-GY023
Phase II
Drug Class Angiogenesis Inhibitors: VEGFR
Drug Name Cediranib
Alternate Drug Names Recentin, Cediranib maleate, AZD2171
Drugs in Trial Cediranib, Durvalumab, Liposomal doxorubicin, Olaparib, Paclitaxel, Topotecan
Eligible Participant

Platinum resistant ovarian cancer with 2- 5 prior therapies; all patients must have had prior bevacizumab

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Randomized


ORR, PFS, OS, evaluated per RECIST


Ola+Ced+Dur (n=44) vs TPC (Pac, PLD, or Top, n=23):

PFS: 2.9 vs 4.3 months, HR: 1.142 (0.60-2.18, p=0.55)


The non-chemo triplet of olaparib, cediranib and durvalumab does not improve PFS compared to standard chemotherapy


Lee J-M et al. Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023). Ann Oncol (2023) 34(2) abstract 746MO

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.